Kang KT, Sullivan JC, Spradley FT, d=Uscio LV, Katusic ZS, Pollock JS. Antihypertensive therapy increases tetrahydrobiopterin levels and NO/cGMP signaling in small arteries of angiotensin II-infused hypertensive rats. Am J Physiol Heart Circ Physiol 300: H718 -H724, 2011. First published December 10, 2010; doi:10.1152/ajpheart.00393.2010.-We previously reported that small mesenteric arteries from hypertensive rats have increased NOS-derived H 2O2 and reduced NO/cGMP signaling. We hypothesized that antihypertensive therapy lowers blood pressure through a tetrahydrobiopterin (BH4)-dependent mechanism restoring NO/cGMP signaling and endothelial NOS (NOS3; eNOS) phosphorylation in small arteries. To test this hypothesis, small mesenteric arteries from normotensive rats (NORM), angiotensin II-infused rats (ANG), ANG rats with triple therapy (reserperine, hydrochlorothiazide, and hydralazine), or ANG rats with oral BH 4 therapy were studied. Both triple therapy and oral BH4 therapy attenuated the rise in systolic blood pressure in ANG rats and restored NO/cGMP signaling in small arteries similarly. Triple therapy significantly increased vascular BH4 levels and BH4-to-BH2 ratio similar to ANG rats with BH4 supplementation. Furthermore, triple therapy (but not oral BH 4 therapy) significantly increased GTP cyclohydrolase I (GTPCH I) activity in small arteries without a change in expression. NOS3 phosphorylation at Ser1177 was reduced in small arteries from ANG compared with NORM, while NOS3 phosphorylation at Ser633 and Thr495 were similar in ANG and NORM. NOS3 phosphorylation at Ser1177 was restored with triple therapy or oral BH 4 in ANG rats. In conclusion, antihypertensive therapy regulates NO/cGMP signaling in small arteries through increasing BH 4 levels and NOS3 phosphorylation at Ser1177. hypertension; nitric oxide synthase; small mesenteric arteries; triple therapy NITRIC OXIDE (NO)/CYCLIC GUANOSINE monophosphate (cGMP) signaling regulates a variety of vascular functions. Reduced NO production and/or bioavailability contributes to vascular dysfunction in many cardiovascular diseases, including hypertension. Loss of nitric oxide synthase (NOS)-mediated vasorelaxation is associated with reduced NO bioavailability and reduced NO/cGMP signaling in conduit arteries studied from animal models of hypertension (23, 27) . In contrast, we (20, 34) previously reported that NOS-mediated vasorelaxation was maintained in small arteries from hypertensive rats through activation of NOS-derived H 2 O 2 , yet NO/cGMP signaling was still reduced in the small arteries. This finding is despite the fact that we and others have previously shown that endothelial NOS (NOS3; eNOS) protein expression is unchanged or even increased in the vasculature in hypertensive animal models such as angiotensin II-infused hypertensive rats (ANG; Ref. 38), DOCA-salt induced hypertensive rats (38), spontaneously hypertensive rats (SHR; Ref. 29), and atherosclerotic apolipoprotein E (apo E)-deficient mice (24). These data suggest that a mechanism other than reduced NOS protein expression is responsible for decreased NO/cGMP signaling in small arteries. The goal of this study was to elucidate the molecular mechanism(s) driving reduced NO/cGMP signaling in small arteries under hypertensive conditions. Tetrahydrobiopterin (BH 4 ) is an essential cofactor regulating NOS activity. BH 4 is synthesized through two distinct pathways: the de novo biosynthetic pathway and the salvage pathway. In endothelial cells, BH 4 levels are regulated by the activity of guanosine triphosphate cyclohydrolase I (GTPCH I), a rate-limiting enzyme in the de novo biosynthesis of BH 4 (5). Reduction of BH 4 levels occurs via decreased GTPCH I activity and/or increased BH 4 oxidation to 7,8-dihydrobiopterin (BH 2 ). BH 2 may also compete for binding to NOS at the BH 4 site, thus promoting NOS uncoupling and loss of NO production (22, 41) . Several studies have shown that decreased BH 4 levels and correspondingly increased levels of BH 2 are present in aorta from diabetic rats (37) and hypertensive mice (23). Laursen et al. (24) have demonstrated that increased peroxynitrite in aorta from atherosclerotic apo E-deficient mice oxidizes vascular BH 4 to BH 2 , thereby uncoupling NOS activity and resulting in impaired endothelium-dependent relaxation. In contrast, endothelial-specific GTPCH I overexpression attenuates the rise in blood pressure and preserves BH 4 levels, NOS3 phosphorylation, and vasorelaxation in a model of salt-sensitive hypertension (9). It is well understood that small arteries have multiple endothelium-dependent vasorelaxation pathways; thus NOS activation and endothelial dysfunction under hypertensive conditions are most likely differentially regulated compared with conduit vessels (12, 18, 20, 26) . Very few studies have focused on BH 4 -dependent changes in NO/cGMP signaling in small arteries.
NITRIC OXIDE (NO)/CYCLIC GUANOSINE monophosphate (cGMP) signaling regulates a variety of vascular functions. Reduced NO production and/or bioavailability contributes to vascular dysfunction in many cardiovascular diseases, including hypertension. Loss of nitric oxide synthase (NOS)-mediated vasorelaxation is associated with reduced NO bioavailability and reduced NO/cGMP signaling in conduit arteries studied from animal models of hypertension (23, 27) . In contrast, we (20, 34) previously reported that NOS-mediated vasorelaxation was maintained in small arteries from hypertensive rats through activation of NOS-derived H 2 O 2 , yet NO/cGMP signaling was still reduced in the small arteries. This finding is despite the fact that we and others have previously shown that endothelial NOS (NOS3; eNOS) protein expression is unchanged or even increased in the vasculature in hypertensive animal models such as angiotensin II-infused hypertensive rats (ANG; Ref. 38) , DOCA-salt induced hypertensive rats (38) , spontaneously hypertensive rats (SHR; Ref. 29) , and atherosclerotic apolipoprotein E (apo E)-deficient mice (24) . These data suggest that a mechanism other than reduced NOS protein expression is responsible for decreased NO/cGMP signaling in small arteries. The goal of this study was to elucidate the molecular mechanism(s) driving reduced NO/cGMP signaling in small arteries under hypertensive conditions.
Tetrahydrobiopterin (BH 4 ) is an essential cofactor regulating NOS activity. BH 4 is synthesized through two distinct pathways: the de novo biosynthetic pathway and the salvage pathway. In endothelial cells, BH 4 levels are regulated by the activity of guanosine triphosphate cyclohydrolase I (GTPCH I), a rate-limiting enzyme in the de novo biosynthesis of BH 4 (5) . Reduction of BH 4 levels occurs via decreased GTPCH I activity and/or increased BH 4 oxidation to 7,8-dihydrobiopterin (BH 2 ). BH 2 may also compete for binding to NOS at the BH 4 site, thus promoting NOS uncoupling and loss of NO production (22, 41) . Several studies have shown that decreased BH 4 levels and correspondingly increased levels of BH 2 are present in aorta from diabetic rats (37) and hypertensive mice (23) . Laursen et al. (24) have demonstrated that increased peroxynitrite in aorta from atherosclerotic apo E-deficient mice oxidizes vascular BH 4 to BH 2 , thereby uncoupling NOS activity and resulting in impaired endothelium-dependent relaxation. In contrast, endothelial-specific GTPCH I overexpression attenuates the rise in blood pressure and preserves BH 4 levels, NOS3 phosphorylation, and vasorelaxation in a model of salt-sensitive hypertension (9) . It is well understood that small arteries have multiple endothelium-dependent vasorelaxation pathways; thus NOS activation and endothelial dysfunction under hypertensive conditions are most likely differentially regulated compared with conduit vessels (12, 18, 20, 26) . Very few studies have focused on BH 4 -dependent changes in NO/cGMP signaling in small arteries.
Phosphorylation at multiple sites of NOS3 is another critical determinant of NOS3 activity. Phosphorylation of NOS3 at Ser1177 and Ser633 and dephosphorylation at Thr495 stimulate NOS3 activity and consequently augment NO/cGMP signaling in bovine aortic endothelial cells (28) . Altered phosphorylation of NOS3, mainly Ser1177, has been observed in conduit arteries from hypertensive models such as two-kidney, one-clip hypertensive rats (16) and DOCA-salt hypertensive rats (34) . However, there is a paucity of information regarding changes in phosphorylation of NOS3 in small arteries under hypertensive conditions.
We are interested in deciphering the dynamic relationship between changes in blood pressure and NOS3 regulation in small arteries. Specifically, there is a lack of knowledge whether blood pressure, per se, influences BH 4 /BH 2 levels and phosphorylation of NOS3 in small arteries. We hypothesized that antihypertensive therapy lowers blood pressure through a BH 4 -dependent mechanism restoring NO/cGMP signaling and NOS3 phosphorylation in small arteries. We treated ANG rats with BH 4 supplementation or triple therapy (reserperine, hydrochlorothiazide, and hydralazine) to lower blood pressure via specific or nonspecific mechanisms, respectively. Total biopterin, BH 4 , BH 2 , and GTPCH I activity and expression were evaluated in isolated small mesenteric arteries as well as measures of vascular NOS signaling, which included the following: cGMP accumulation, monomer-to-dimer ratio of NOS3 protein, and phosphorylation of NOS3.
METHODS
Animal models. Male Sprague-Dawley rats (200 -250 g; Charles River Laboratories, Wilmington, MA) were divided into four groups: normotensive rats (NORM), ANG, ANG with triple therapy (ANG ϩ TT; as follows in mg·kg Ϫ1 ·day Ϫ1 : 30 hydralazine, 10 hydrochlorothiazide, and 0.5 reserpine), and ANG with a supplementation of BH4 (100 mg·kg Ϫ1 ·day Ϫ1 ; Schircks Laboratories, Switzerland: ANG ϩ BH4). The dose and route of administration were previously shown to be efficacious (19, 21, 23, 40) . To establish ANG II-infused hypertension, an osmotic mini-pump containing angiotension II was implanted subcutaneously into rats under isoflurane anesthesia (IsoFlo; Abbott Laboratories, North Chicago, IL). ANG II was infused chronically at the rate of 70 ng/min for 2 wk. BH4 treatment was initiated 3 days before starting ANG II infusion and was continued throughout the 2-wk ANG II treatment period. BH4 was administered daily by gavage (100 mg·kg Ϫ1 ·day Ϫ1 ) for 3 days before and throughout the 2-wk period of ANG II infusion. TT was provided in the drinking water for 3 days before and throughout the 2-wk period of ANG II infusion. The TT solution was changed every three days and modified according to the amount of water intake for each rat. Systolic blood pressure was measured after 7 and 14 days of ANG II infusion by tail-cuff plethsomyography as previously described (33) . Systolic blood pressure of each rat was determined by the average of four to six independent readings. After 2 wk, rats were anesthetized with pentobarbital sodium (Nembutal; 50 mg/kg ip; Abbott) and small mesenteric arteries were isolated as previously described (38) . Isolated small mesenteric arteries were homogenized in extraction buffer [as follows in mmol/l: 50 Tris (pH 7.4), 1 dithiothreitol, and 1 EDTA] at 4°C and centrifuged at 10,000 g (8 min at 4°C). Biopterin levels were determined after differential oxidation in acid (which converts both BH 4 and 7,8-BH2 to biopterin) and base (which converts only 7,8-BH2 to biopterin) conditions by reverse-phase HPLC (Beckman Coulter, Fullerton, CA) with a fluorescence detector (Jasco) as described previously (7). Data were collected and analyzed by 32 Karat chromatography software (Beckman Coulter) and normalized against tissue protein levels. BH 4 content was calculated from the difference in biopterin levels after acid and base oxidation.
Measurement of intracellular GTPCH I activity. Tissue supernatant homogenates, prepared as in the biopterin assay, were filtered using a Sephadex G25M column (Amersham, Piscataway, NJ) to remove endogenous neopterin, BH 4, and phenylalanine. GTPCH I enzymatic activity was assayed using reverse-phase HPLC method (Beckman Coulter) by measurements of neopterin, which was derived from dihydroneopterin triphosphate after oxidation and phosphate treatment (7) .
Measurement of intracellular cGMP content. Small mesenteric arteries were isolated, cleaned, divided into two sections, and incubated at 37°C in oxygenated PSS containing IBMX (300 mol/l) for 15 min. Additional arterial segments were incubated with a nonselective NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME; 100 mol/l) for 15 min. Arterial segments were snap-frozen in liquid nitrogen immediately after incubation and homogenized in ice cold 10% TCA (LabChem, Pittsburgh, PA). TCA homogenates were extracted with ether, and cGMP levels were quantitated by radioimmunoassay and normalized to milligrams of protein content as described previously (34) . Protein concentrations were determined by standard Bradford assay (Bio-Rad Laboratories, Hercules, CA) using BSA as the standard.
Immunoblotting. Arterial segments were snap-frozen in liquid nitrogen and homogenized in cold homogenization buffer (20.0 mmol/l Tris·HCl with pH 7.4, 137.0 mmol/l NaCl, 10% glycerol, and 1% NP40) containing protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and phosphatase inhibitor cocktail (Pierce, Pockford, IL). Protein concentrations were determined by standard Bradford assay, and Western blotting and low-temperature SDS-PAGE were performed as described previously (6, 35, 42) . Briefly, after proteins were transferred to PVDF or nitrocellulose membranes, they were blocked in blocking buffer (Nacalai USA, San Diego, CA). Membranes were probed using primary antibody against GTPCH I (Ascenion, Munich, Germany), and, as a loading control, blots were rehybridized with monoclonal anti-␤-actin (Sigma). For others, twocolor immunoblots were performed using primary antibodies to NOS3 (BD Transduction laboratory, San Jose, CA), phosphorylated NOS3-Ser1177 (Cell Signaling, Danvers, MA), phosphorylated NOS3-Ser633 (Upstate, Lake Placid, NY), phosphorylated NOS3-Thr495 (Upstate, Lake Placid, NY), Akt (Cell Signaling), phosphorylated Akt-Ser473 (Cell Signaling), and ␤-actin (Sigma, St. Louis, MO). Specific bands were detected using the Odyssey Infrared Imager. IRDye800 (Rockland, Gilbertsville, PA) and AlexaFluor 680 (Molecular Probes, Eugene, OR) were used as secondary antibodies for the detection of two different primary antibodies. Densitometry was analyzed for NOS3, phosphorylated NOS3, Akt kinase, phosphorylated Akt kinase, and ␤-actin. Relative densitometric units for NOS3 and Akt were calculated by normalization to ␤-actin levels, while phosphorylated proteins were normalized to the corresponding nonphosphorylated, total protein. Low-temperature SDS-PAGE NOS3 dimer and monomer bands were detected using the Odyssey Infrared Imager.
Materials. ANG II was purchased from Phoenix Pharmaceuticals (Belmont, CA). Mini-osmotic pumps were purchased from Alzet (Cupertino, CA). All other chemicals were purchased from SigmaAldrich (St. Louis, MO).
Data analysis. Values are expressed as means Ϯ SE and analyzed by Student's t-test for paired comparison or ANOVA followed by a Bonferroni's correction for multiple comparisons (Prism, La Jolla, CA). A value of P Յ 0.05 was considered statistically significant.
RESULTS
Systolic blood pressure. Systolic blood pressure was significantly greater in ANG compared with NORM following 1 wk of infusion, and this difference in pressure was maintained through the following weeks (n ϭ 19 -21; Fig. 1 ). Treatment with either TT or BH 4 in the ANG group significantly blocked the increase in blood pressure at week 1 and attenuated the increase in pressure at week 2.
BH 4 , BH 2 content, and BH 4 -to-BH 2 ratio in small mesenteric arteries. As shown in Fig. 2 (n ϭ 10) , BH 4 levels in small arteries from the ANG group was not different from NORM. However, concomitant treatment with either TT or BH 4 significantly increased BH 4 levels ( Fig. 2A) . Treatment with BH 4 further increased BH 4 levels ( Fig. 2A) . BH 2 levels showed a tendency to increase in the ANG group (P ϭ 0.07 compared with NORM group; Fig. 2B ). This in turn significantly decreased the percentage BH 4 of total biopterin (Fig. 2C) and BH 4 -to-BH 2 ratio (Fig. 2D ) in small arteries from ANG compared with NORM. TT or BH 4 supplementation did not affect BH 2 levels in ANG (Fig. 2B) . However, the percentage BH 4 of total biopterin and the BH 4 -to-BH 2 ratio was restored with either TT or BH 4 treatment (Fig. 2, C and D, respectively; P Ͻ 0.05, compared with the untreated ANG group).
GTPCH I enzymatic activity and protein expression in small mesenteric arteries. To evaluate the mechanism of increased BH 4 level in ANG with TT, GTPCH I enzymatic activity and protein expression were determined. GTPCH I activity was not changed in ANG group compared with NORM group (n ϭ 6 -7; Fig. 3A) . GTPCH I activity was significantly increased with TT but not with BH 4 supplementation (n ϭ 6 -7; Fig. 3A) . GTPCH I protein expression was similar between groups (n ϭ 3; Fig. 3B) .
cGMP in small mesenteric arteries. NO/cGMP signaling in small mesenteric arteries was assessed by measuring the cGMP content in the presence and absence of L-NAME (n ϭ 6; Fig. 4 ). cGMP accumulation in small arteries from ANG was significantly less compared with the NORM group (Fig. 4A) . cGMP levels were restored by both antihypertensive treatments (Fig. 4A) . Preincubation with L-NAME abolished cGMP accumulation in NORM and ANG (data not shown), confirming that cGMP levels were dependent on NOS-mediated signaling and consistent with our previous publication (20) .
NOS3 monomer-to-dimer ratio. The native state of NOS3 is as a dimer (42) . Increased NOS3 monomers, reported as an increase in the monomer-to-dimer ratio, has been used as a marker of NOS3 uncoupling in conduit arteries (44) . Lowtemperature SDS-PAGE analysis revealed that NOS3 is expressed predominately as the native dimer form in small arteries from both NORM and ANG (Fig. 4B) .
Total and phosphorylated NOS3 and Akt kinase. Since NOS3-mediated NO/cGMP signaling is regulated dynamically through phosphorylation and dephosphorylation (28) and phosphorylation status may modulate NOS3 activity and uncoupling (25), we analyzed phosphorylation of NOS3 at Ser1177, Fig. 1 . Systolic blood pressure of normotensive rats (NORM; n ϭ 19), ANG rats (n ϭ 19), ANG rats with triple therapy (ANG ϩ TT; n ϭ 21), and ANG rats with tetrahydrobiopterin (ANG ϩ BH4; n ϭ 21) before and after 1 and 2 wk of ANG II infusion. *Significant difference vs. NORM at each period (P Յ 0.05).
† Significant difference vs. ANG at each period (P Յ 0.05). Ser633, and Thr495 in small mesenteric arteries ( Fig. 5 ; n ϭ 5-13). Total NOS3 protein expression was comparable between groups (n ϭ 5-13; Fig. 5A ). Phosphorylation of NOS3 at Ser1177 in small arteries from ANG rats was significantly less than NORM rats. Furthermore, NOS3 phosphorylation at Ser1177 site was restored when blood pressure was lowered with either treatment (Fig. 5B) . Phosphorylation of NOS3 at Ser633 and Thr495 was similar in ANG and NORM rats (n ϭ 10 -11; Fig. 6A and B) . Phosphorylation at Ser1177 of NOS3 is regulated by Akt kinase activation (13, 28, 36) , while ANG II increases Akt phosphorylation at Ser473 in renal thick ascending limb (15). Thus we analyzed total and phosphorylated Akt at Ser473 in small mesenteric arteries from NORM and ANG rats (n ϭ 7; Fig. 7 ). We found that total Akt is greater in small arteries from ANG rats compared with NORM (Fig. 7A) . However, the ratio of phosphorylated Akt to total Akt was not significantly different (Fig. 7B) .
DISCUSSION
The present study focused on the blood pressure-dependent regulation of BH 4 -to-BH 2 levels, GTPCH I activity, NO/cGMP signaling, and NOS3 phosphorylation in small mesenteric arteries. We found that the antihypertensive treatments, triple therapy, or oral BH 4 increased vascular BH 4 levels and the BH 4 -to-BH 2 ratio, restored NO/cGMP signaling, and restored NOS3 phosphorylation at Ser1177. Furthermore, triple therapy (but not oral BH 4 therapy) significantly increased GTPCH I activity in small arteries without a change in GTPCH I expression. In addition, we found that NOS3 monomerization, NOS3 phosphorylation at Ser633 and Thr495, and Akt phosphorylation at Ser473 in small mesenteric arteries were not altered despite changes in blood pressure. These data indicate that the increase in BH 4 levels and consequently the increase in NO/ cGMP signaling lowered blood pressure.
Vascular BH 4 -to-BH 2 ratio and blood pressure regulation. BH 4 is an essential cofactor for NO biosynthesis, and BH 4 deficiency has been shown to be a primary mechanism for NOS uncoupling (1, 2, 22) . In addition to the reduction of absolute BH 4 levels, a decrease in the ratio between the fully reduced BH 4 and oxidized BH 2 may also contribute to NOS3 uncoupling (5, 41) . A reduced vascular BH 4 -to-BH 2 ratio was observed in studies from apo E-deficient mice (8) and diabetic (db/db) mice (32), whereas absolute BH 4 levels have been shown to be either increased in apo E-deficient mice (7), unchanged in diabetic (db/db) mice (32) and ANG II-infused hypertensive rats (21) , or decreased in insulin-resistant rats (37), spontaneously hypertensive rats (17) , apo E-deficient mice (24) , and DOCA-salt mice (9) . BH 2 is not a NOS cofactor but may effectively reduce NO bioavailability by competitively binding to NOS3 at the BH 4 binding site resulting in loss of NO production and enhancement of NOS uncoupling (5, 41) . Vasquez-Vivar et al. (41) demonstrated that both coupled and uncoupled NOS3 activity may exist when both BH 4 and BH 2 are present utilizing an in vitro system. The current study furthers this observation by demonstrating that triple therapy and oral BH 4 increased the BH 4 -to-BH 2 ratio in small arteries. Previously, we reported that NOS generates both NO and H 2 O 2 in small arteries from ANG II-infused hypertensive rats (20) . The data in the current study support the hypothesis that the ratio of BH 4 to BH 2 is a critical determinant for NOS uncoupling in small arteries in ANG II-induced hypertension. Fig. 3 . A: GTP cyclohydrolase I (GTPCH I) enzymatic activity in small mesenteric arteries (n ϭ 6 -7) from NORM, ANG, ANG ϩ TT, and ANG ϩ BH4. *Significant difference vs. NORM (P Յ 0.05). †Significant difference vs. ANG (P Յ 0.05). #Significant difference vs. ANG ϩ TT (P Յ 0.05). B: representative Western blot and relative densitometry analysis of GTPCH I protein expression normalized to ␤-actin in small mesenteric arteries (n ϭ 3) from NORM, ANG, ANG ϩ TT, and ANG ϩ BH4. Fig. 4 . A: cGMP accumulation in small mesenteric arteries (n ϭ 6) from NORM, ANG, ANG ϩ TT, and ANG ϩ BH4. *Significant difference vs. NORM (P Յ 0.05). †Significant difference vs. ANG (P Յ 0.05). B: representative Western blot analysis of low-temperature SDS-PAGE evaluation of endothelial NOS (NOS3) dimer and monomer in small mesenteric arteries (n ϭ 4) from NORM and ANG.
Oral BH 4 therapy dramatically increased tissue levels of BH 4 , yet BH 2 levels did not follow resulting in an increased BH 4 -to-BH 2 ratio in small arteries. BH 4 is known to have antioxidant effects independent of its role as a cofactor for NOS (22) . However, our data suggest that the antioxidant activity of oral BH 4 therapy does not influence BH 4 oxidation to BH 2 in small arteries. Yet, substantial reduction of tissue O 2 Ϫ production was previously demonstrated in aortic tissue from DOCA-salt hypertensive mice with oral BH 4 therapy (23). Interestingly, triple therapy significantly increased BH 4 levels and in turn the BH 4 -to-BH 2 ratio in small arteries similar to oral BH 4 therapy. Blood pressure, per se, does not appear to play a role in the regulation of GTPCH I activity in small arteries, since this is similar in normotensive and hypertensive rats. Triple therapy increased GTPCH I enzymatic activity without a concomitant change in protein expression, suggesting that the treatment paradigm activates GTPCH I. At this point, there is a lack of knowledge regarding whether reserpine, hydrochlorothiazide, and/or hydralazine directly influence GTPCH I activity. Further experimentation is necessary to determine the mechanism of triple therapy mediated activation of GTPCH I.
NO/cGMP signaling in small arteries and blood pressure regulation. Our laboratory and others (20, 34) have demonstrated reduced NO/cGMP signaling in arteries from various hypertensive animal models. The present study confirmed our previous observation that small mesenteric arteries from hypertensive rats have reduced cGMP accumulation. Triple therapy and oral BH 4 both reduced blood pressure to similar levels in the ANG II-dependent model of hypertension after 1 and 2 wk of treatment. Expectedly, BH 4 supplementation increased vascular NO/cGMP signaling. Interestingly, lowering blood pressure via triple therapy also increased vascular NO/cGMP signaling. Several reports (40) have shown that triple therapy does not influence the renin-ANG-aldosterone system, most likely excluding this possibility in the mechanism. Blood pressure dependent changes in NO/cGMP signaling have previously been reported in the two-kidney, one-clip model of hypertension (43) in agreement with our study. Furthermore, Du et al. (9) showed that NOS3 uncoupling was attenuated in DOCA-salt hypertensive mice with an endothelial-specific overexpression of GTPCH I increasing BH 4 synthesis and the vascular BH 4 -to-BH 2 ratio along with a reduction in blood pressure. These data support the hypothesis that vascular NO/ cGMP signaling via changes in the BH 4 -to-BH 2 ratio regulates blood pressure.
In vitro studies have demonstrated that the native dimer state of NOS3 generates NO, while monomer expression has been associated with NOS3 uncoupling (11) and increases in the monomer- to-dimer ratio has been used in many studies with conduit arteries as a marker of NOS3 uncoupling (44) . We found that native NOS3 was expressed as dimers in small arteries from both normotensive and ANG II-induced hypertensive rats. Therefore, since we have previously published that NOS generates H 2 O 2 in small mesenteric arteries from hypertensive rats, the monomerto-dimer ratio of NOS3 does not appear to be related to enzymatic uncoupling of NOS3, at least, in small arteries. Similarly, Du et al. (9) found increased NOS-mediated O 2 Ϫ production with no increase in monomerization of NOS3 in small mesenteric arteries from DOCA-salt hypertensive mice. These data indicate that NOS3 monomer in small arteries is unrelated to blood pressure or NOS3 uncoupling.
NOS3 phosphorylation in small arteries and blood pressure regulation. In the present study, we demonstrated that NOS3 phosphorylation at Ser1177 was reduced in small arteries from ANG. These data indicate that reduced NO/cGMP signaling in small arteries from hypertensive rats may be due, in part, to dysfunctional phosphorylation at Ser1177. Numerous studies (16, 34) have demonstrated reduced NOS3 phosphorylation at Ser1177 in the vasculature from hypertensive animal models. However, the dynamic change of NOS3 phosphorylation in small arteries by reduction of blood pressure has rarely been studied. We demonstrate that NOS3 phosphorylation at Ser1177 is restored with triple therapy and oral BH 4 , suggesting that the Ser1177 phosphorylation site is blood pressure dependent. The Ser1177 phosphorylation site is linked to shear stress-mediated activation of NOS3 in cultured endothelial cells (4); thus we hypothesize that lowering blood pressure leads to a functional recoupling of the Ser1177 phosphorylation pathway in vivo. In studies with endothelial cells, the serine/threonine kinase Akt has been identified as a major kinase contributing to the phosphorylation at the Ser1177 site (13) . Akt activity is also regulated by posttranslational phosphorylation at Ser473 in endothelial cells (14) . In our results, Akt phosphorylated at Ser473 in small mesenteric arteries from hypertensive rats shows a tendency to increase compared with the normotensive control (P ϭ 0.07), which may be due to the ANG II and not blood pressure (15) . Reports of the regulation of Akt phosphorylation in the vasculature under hypertensive conditions show inconsistent results: decreased in DOCA (31) and obese Zucker rats (30) , unchanged in N G -nitro-L-argininetreated rat (31) and DOCA (34) , or increased in two-kidney, one-clip (16) and ANG II infusion (3). This discrepancy may be due to the level of hypertension as well as the type of vascular tissue examined. It should also be noted that Akt measurements in endothelium-intact vascular tissue may not be reflective of endothelial-dependent changes and may be a result of changes in smooth muscle-derived Akt. Our results suggest that Akt activation under ANG II infusion does not associate with the dysfunctional NOS3 phosphorylation at Ser1177 in small arteries. NOS3-bound Akt may regulate NOS3 activity more precisely than total Akt (10, 39) . Thus further investigation is needed to determine the phosphorylation status of Akt and NOS3 from vascular tissues in hypertensive animal models.
We previously reported that NOS activity generates both NO and H 2 O 2 in small arteries from hypertensive rats, indicating that both coupled and uncoupled NOS are present. NOS3 phosphorylation at Ser633 and Thr495 was similar in small arteries from hypertensive and normotensive rats. Therefore, these data led us to hypothesize that phosphorylation at Ser633 and Thr495 is responsible for maintenance of basal NO production and NO/cGMP signaling in small arteries. Further investigation is necessary to fully elucidate this possible mechanism.
In conclusion, the present study demonstrates that de novo biosynthesis of BH 4 via GTPCH I or supplementation of BH 4 leading to increased NO/cGMP signaling and NOS3 phosphorylation at Ser1177 results in lowering blood pressure. Further evaluation of the molecular mechanisms underlying antihypertensive therapy and activation of GTPCH I may lead to novel therapies to activate and restore NO/cGMP signaling.
